Since the Supreme Court overturned Roe v. Wade in June 2022, the number of abortions in the United States has not decreased — in fact, it has increased. This is the central paradox that the Supreme Court's ruling on May 15, 2026 underscores once again: banning abortion at the constitutional level is one thing, but controlling access to abortion medication through the mail is something entirely different.
This is a legal assault on drug distribution infrastructure, not on the act of abortion itself.
The Big Picture: What Is Mifepristone and Why Does It Matter So Much
Mifepristone is a drug approved by the U.S. Food and Drug Administration (FDA) in 2000, typically used in combination with misoprostol to end early pregnancy. According to data from the Guttmacher Institute, it is currently the most common method of abortion in the United States — accounting for more than 60 percent of all abortions nationwide as of 2023. Of those, according to NPR, approximately one-quarter of abortions currently take place through telemedicine: patients connect with doctors over the phone or internet, receive prescriptions, and receive medication through the mail at home.
This is why the order issued by the Fifth Circuit Court of Appeals on May 1, 2026 caused such upheaval: this order would ban the mailing of mifepristone nationwide — not just in states that have banned abortion, but also in places where abortion is entirely legal such as California and New York. This is a legal assault on drug distribution infrastructure, not on the act of abortion itself.
On May 15, 2026, the Supreme Court suspended that order, preserving access to mifepristone through telemedicine while the case continues to be reviewed in lower courts. The order was issued at around 5:30 p.m. — about 30 minutes after the Court's self-imposed deadline — and was accompanied by public dissent from two justices, Samuel Alito and Clarence Thomas.
Alito and the "Conspiracy" Against Dobbs: When Dissent Becomes Political Manifesto
Alito's dissent was not merely a conventional legal argument. He called the majority's suspension order "unreasoned" and "remarkable," then presented a highly controversial thesis: he contended that allowing mifepristone to be sent through the mail is "a scheme to undermine the Dobbs decision" — the 2022 decision he himself authored that overturned Roe v. Wade.
This argument is problematic both legally and logically. Dobbs merely declared that the U.S. Constitution does not guarantee a right to abortion, returning the power to regulate the issue to individual states. But Alito is implying that Dobbs must also mean that states have the power to restrict access to abortion medication in other states — an argument about reversed federal preemption that contradicts the principle of state sovereignty that Dobbs itself invoked.
Alito's argument actually opens up a larger legal question that the courts will eventually have to face: Can one state ban residents of another state from receiving abortion medication through the mail? The Supreme Court has not yet answered this question. But by publicly raising it in his dissent, Alito is anchoring the framework for future rounds of litigation.
FDA's Absence: Sign of a Paralyzed Administration
One of the most notable details in this case is that the FDA — the main defendant in the lawsuit — did not file any documents with the Supreme Court when asked to do so. This is profoundly unusual: typically, an executive agency has an obligation to defend its own regulations before the courts.
Instead, according to analysis by law professor Mary Ziegler at the University of California Davis, the Trump administration is deliberately "kicking the ball down the road" to avoid having to take a clear stance on abortion rights before the midterm elections. Ziegler told NPR bluntly: "This is a thorny political issue — neither the Republican base voters nor the swing voters agree with each other on abortion policy.
The FDA's silence also raises institutional questions: if the drug regulatory agency refuses to defend regulations it itself issued, who will protect them? In this case, the burden has been transferred to a coalition of nearly 24 Democratic-led states — states that filed amicus curiae briefs with the court, arguing that the Fifth Circuit's ruling puts the policies of states with abortion bans above the sovereignty of states that have chosen to guarantee access to these services.
This week, the FDA descended further into chaos when FDA Commissioner Marty Makary resigned under pressure from the White House. According to NPR, anti-abortion groups publicly expressed frustration that Makary had not done enough to restrict mifepristone during his tenure.
The FDA's Authority Under Threat: A Larger Systemic Risk Than Abortion Medication
What receives less attention in the abortion debate is the institutional danger that the Louisiana lawsuit creates for the entire FDA drug approval system.
A coalition of former FDA leadership — who served under both Democratic and Republican administrations — filed an amicus brief warning that the Fifth Circuit's ruling "would overturn the science-based drug approval system that is the FDA's gold standard." The pharmaceutical industry trade group PhRMA also filed a similar brief, arguing that pharmaceutical companies "have a substantial interest in protecting themselves from disruption to the stable and predictable legal framework that Congress created to regulate the FDA.
This is a sign that this legal battle has transcended the scope of abortion debate. If federal courts can reexamine the FDA's scientific approval process based on moral or political grounds, there is no reason to limit that principle only to mifepristone. Vaccines, HIV medications, contraceptives — all could be challenged under the same logic.
The Vietnamese American Community: Underheard Layers of Impact
The Vietnamese American community is not homogeneous in its views on abortion — and this is a fact that any honest analysis must acknowledge. According to data from the Pew Research Center, Asian Americans generally tend to support abortion rights at rates higher than the national average, but within the Vietnamese community — particularly in heavily Catholic communities like Little Saigon in Orange County and Houston, Texas — conservative views on abortion are fairly common.
However, the question of access to healthcare through telemedicine is another matter entirely. Many Vietnamese American families — especially second and third generation young women — live in states like California and Virginia, where abortion is entirely legal. For these people, telemedicine is not just a convenience but a way to lower language and cultural barriers: no need to go to a clinic, no need to explain to relatives, no need to face community pressure.
Particularly important is the group of Vietnamese women without health insurance or with limited insurance — a common reality in the immigrant working communities in states like Texas and Georgia, where both abortion bans and insurance barriers exist simultaneously. For them, access to mifepristone through telemedicine from legal states may be the only viable option.
Misoprostol: The Alternative and Its Healthcare Costs
Immediately after the Fifth Circuit's ruling on May 1, 2026, some telemedicine providers announced they would switch to using higher-dose misoprostol alone — a regimen that researchers confirm is "safe and equivalently effective," according to NPR. However, this regimen typically causes more side effects, including nausea and diarrhea.
This is a vivid illustration of an important public health principle: bans do not eliminate need, they only shift need to less favorable options. For women who cannot take time off work, who have no childcare, or who live far from medical facilities, this difference in side effects is not a minor issue.
Looking Ahead: Three Scenarios for the Louisiana Case
The Louisiana lawsuit against the FDA is now back in lower courts for continued proceedings. There are three main scenarios that could play out:
- Scenario 1 — Fifth Circuit maintains mail ban: If the Fifth Circuit rules in this direction in its final judgment, the case will almost certainly escalate to the Supreme Court, forcing the nine justices to make a substantive ruling rather than just a temporary suspension.
- Scenario 2 — Fifth Circuit reverses or narrows its ruling: Less likely, but if there is sufficient political pressure — for example after the 2026 midterm elections — the court could adjust its position.
- Scenario 3 — Congress acts: The least likely scenario in the short term, but theoretically Congress could legislate to clearly protect the right to mail FDA-approved drugs through the federal mail system.
- Regardless of which scenario unfolds, 2026 is a midterm election year — and according to Professor Ziegler's analysis, the Trump administration will continue to avoid taking a clear stance on abortion for as long as possible. The FDA's absence from this lawsuit is not an accident; it is a strategy.
Conclusion: Status Quo Preserved, But the Battle Is Far From Over
The Supreme Court's ruling on May 15, 2026 resolves nothing substantively. It merely maintains the status quo while the legal machinery continues to turn. But that is not bad news for those who support access to abortion services: in this case, the status quo means that hundreds of thousands of American women each year can still receive the medication they need through the mail.
What is more concerning is the legal architecture that mifepristone opponents are building brick by brick — from the Fifth Circuit to the public dissents of Alito and Thomas. The long-term objective is not merely mifepristone: it is to establish a court precedent allowing conservative states to interfere with federal drug supply chains on moral grounds. If that precedent succeeds, the impact will extend far beyond abortion medication.
Saigon Sentinel will continue to monitor the Louisiana case as it progresses through lower courts — and especially what happens to the FDA after Makary leaves his position as commissioner.